Proteomics: Potential techniques for discovering the pathogenesis of connective tissue diseases-interstitial lung disease

Interstitial lung disease (ILD) is one of the most serious lung complications of connective tissue disease (CTD). The application of proteomics in the past decade has revealed that various proteins are involved in the pathogenesis of each subtype of CTD-ILD through different pathways, providing novel ideas to study pathological mechanisms and clinical biomarkers. On this basis, a multidimensional diagnosis or prediction model is established. This paper reviews the results of proteomic detection of different subtypes of CTD-ILD and discusses the role of some differentially expressed proteins in the development of pulmonary fibrosis and their potential clinical applications.

[1]  I. Yang,et al.  Epithelial ER Stress Enhances the Risk of Muc5b Associated Lung Fibrosis. , 2022, American journal of respiratory cell and molecular biology.

[2]  A. Simeonov,et al.  A small-molecule inhibitor and degrader of the RNF5 ubiquitin ligase , 2022, Molecular biology of the cell.

[3]  M. Weinblatt,et al.  Serum proteomic profiling of rheumatoid arthritis–interstitial lung disease with a comparison to idiopathic pulmonary fibrosis , 2022, Thorax.

[4]  J. M. Bravo-San Pedro,et al.  Mitochondrial Oxidative Stress Induces Cardiac Fibrosis in Obese Rats through Modulation of Transthyretin , 2022, International journal of molecular sciences.

[5]  N. McElvaney,et al.  Targeting of Glycosaminoglycans in Genetic and Inflammatory Airway Disease , 2022, International journal of molecular sciences.

[6]  J. Muenzer,et al.  Chemically modified recombinant human sulfamidase (SOBI003) in mucopolysaccharidosis IIIA patients: Results from an open, non-controlled, multicenter study. , 2022, Molecular genetics and metabolism.

[7]  Dahai Zhao,et al.  Biomarkers of connective tissue disease‐associated interstitial lung disease in bronchoalveolar lavage fluid: A label‐free mass spectrometry‐based relative quantification study , 2022, Journal of clinical laboratory analysis.

[8]  T. Corte,et al.  Diagnosis of myositis-associated interstitial lung disease: Utility of the myositis autoantibody line immunoassay. , 2021, Respiratory medicine.

[9]  P. Loke,et al.  TNFR2/14-3-3ε signaling complex instructs macrophage plasticity in inflammation and autoimmunity. , 2021, The Journal of clinical investigation.

[10]  D. Ma,et al.  Establishing Classification Tree Models in Rheumatoid Arthritis Using Combination of Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry and Magnetic Beads , 2021, Frontiers in Medicine.

[11]  W. Wuyts,et al.  Economic Burden and Management of Systemic Sclerosis-Associated Interstitial Lung Disease in 8 European Countries: The BUILDup Delphi Consensus Study , 2020, Advances in Therapy.

[12]  G. Nakshbandi,et al.  Home monitoring for patients with ILD and the COVID-19 pandemic , 2020, The Lancet Respiratory Medicine.

[13]  Xinran Liu,et al.  Bioactive Plasma Mitochondrial DNA Is Associated With Disease Progression in Scleroderma‐Associated Interstitial Lung Disease , 2020, Arthritis & rheumatology.

[14]  O. Distler,et al.  Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease , 2020, PloS one.

[15]  Bill B. Chen,et al.  Kelch-like protein 42 is a profibrotic ubiquitin E3 ligase involved in systemic sclerosis , 2020, The Journal of Biological Chemistry.

[16]  H. Cai,et al.  Surfactant protein D is associated with 3-month mortality of anti-MDA5 antibody-interstitial lung disease. , 2020, Clinical and experimental rheumatology.

[17]  S. Danoff,et al.  Interstitial Lung Disease in Polymyositis and Dermatomyositis. , 2019, Clinics in chest medicine.

[18]  Quanzhen Li,et al.  Increased Serum Matrix Metalloproteinase-9 Levels are Associated with Anti-Jo1 but not Anti-MDA5 in Myositis Patients , 2019, Aging and disease.

[19]  Lingxin Chen,et al.  Evaluation of Glutathione S-Transferase Inhibition Effects on Idiopathic Pulmonary Fibrosis Therapy with a Near-Infrared Fluorescent Probe in Cell and Mice Models. , 2019, Analytical chemistry.

[20]  Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality , 2019, The Journal of Rheumatology.

[21]  Kevin K. Brown,et al.  Interstitial lung disease associated with systemic sclerosis (SSc-ILD) , 2019, Respiratory Research.

[22]  R. Zubarev,et al.  Patients with anti-Jo1 antibodies display a characteristic IgG Fc-glycan profile which is further enhanced in anti-Jo1 autoantibodies , 2018, Scientific Reports.

[23]  T. Zheng,et al.  Systems Analysis of Transcriptomic and Proteomic Profiles Identifies Novel Regulation of Fibrotic Programs by miRNAs in Pulmonary Fibrosis Fibroblasts , 2018, Genes.

[24]  A. Fischer,et al.  Rheumatoid Arthritis–Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality , 2018, The Journal of Rheumatology.

[25]  R. Wu,et al.  Genetic Association of Pulmonary Surfactant Protein Genes, SFTPA1, SFTPA2, SFTPB, SFTPC, and SFTPD With Cystic Fibrosis , 2018, Front. Immunol..

[26]  G. Rossi,et al.  The Lung in Rheumatoid Arthritis , 2018, Arthritis & rheumatology.

[27]  L. Hendershot,et al.  SIL1, the endoplasmic-reticulum-localized BiP co-chaperone, plays a crucial role in maintaining skeletal muscle proteostasis and physiology , 2018, Disease Models & Mechanisms.

[28]  F. B. Sørensen,et al.  Localization of surfactant protein‐D in the rheumatoid synovial membrane , 2018, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[29]  G. Burmester,et al.  The Diagnosis and Treatment of Sjögren's Syndrome. , 2017, Deutsches Arzteblatt international.

[30]  G. Riemekasten,et al.  The status of pulmonary fibrosis in systemic sclerosis is associated with IRF5, STAT4, IRAK1, and CTGF polymorphisms , 2017, Rheumatology International.

[31]  G. Raghu,et al.  Interstitial Lung Disease in India. Results of a Prospective Registry , 2017, American journal of respiratory and critical care medicine.

[32]  M. Khurshid,et al.  Proteomics: Technologies and Their Applications. , 2017, Journal of chromatographic science.

[33]  L. Niklason,et al.  Netrin‐1 Regulates Fibrocyte Accumulation in the Decellularized Fibrotic Sclerodermatous Lung Microenvironment and in Bleomycin‐Induced Pulmonary Fibrosis , 2016, Arthritis & rheumatology.

[34]  J. Solomon,et al.  Connective tissue disease-related interstitial lung disease. , 2016, Baillière's Best Practice & Research : Clinical Rheumatology.

[35]  G. Washko,et al.  Functional impact of a spectrum of interstitial lung abnormalities in rheumatoid arthritis. , 2014, Chest.

[36]  T. Radstake,et al.  Proteomic analysis of plasma identifies the Toll-like receptor agonists S100A8/A9 as a novel possible marker for systemic sclerosis phenotype , 2014, Annals of the rheumatic diseases.

[37]  L. Joosten,et al.  Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. , 2014, The New England journal of medicine.

[38]  A. Holland,et al.  Cyclophosphamide for connective tissue disease-associated interstitial lung disease. , 2014, The Cochrane database of systematic reviews.

[39]  Mark S. Anderson,et al.  BPIFB1 Is a Lung-Specific Autoantigen Associated with Interstitial Lung Disease , 2013, Science Translational Medicine.

[40]  A. Prasse,et al.  Towards a functional proteomics approach to the comprehension of idiopathic pulmonary fibrosis, sarcoidosis, systemic sclerosis and pulmonary Langerhans cell histiocytosis. , 2013, Journal of proteomics.

[41]  P. Bradding,et al.  CADM1 Is a Key Receptor Mediating Human Mast Cell Adhesion to Human Lung Fibroblasts and Airway Smooth Muscle Cells , 2013, PloS one.

[42]  M. Strek,et al.  Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. , 2013, Chest.

[43]  Kevin Weiss,et al.  Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. , 2012, American journal of respiratory and critical care medicine.

[44]  Yi-qiang Wang,et al.  Low Concentration of S100A8/9 Promotes Angiogenesis-Related Activity of Vascular Endothelial Cells: Bridges among Inflammation, Angiogenesis, and Tumorigenesis? , 2012, Mediators of inflammation.

[45]  Jing He,et al.  [Screening for serum specific biomarkers in patients with primary Sjögren's syndrome and interstitial lung disease using proteomic fingerprint techniques]. , 2012, Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences.

[46]  P. Boracchi,et al.  Interstitial lung disease outcomes by high-resolution computed tomography (HRCT) in Anti-Jo1 antibody-positive polymyositis patients: a single centre study and review of the literature. , 2012, Autoimmunity reviews.

[47]  Georg Schett,et al.  The pathogenesis of rheumatoid arthritis. , 2011, The New England journal of medicine.

[48]  G. Raghu,et al.  Rheumatoid arthritis-interstitial lung disease-associated mortality. , 2011, American journal of respiratory and critical care medicine.

[49]  D. Ascherman.  Interstitial Lung Disease in Rheumatoid Arthritis , 2010, Current rheumatology reports.

[50]  E. Feierl,et al.  Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database , 2010, Annals of the rheumatic diseases.

[51]  A. Fietta,et al.  2-DE and LC-MS/MS for a comparative proteomic analysis of BALf from subjects with different subsets of inflammatory myopathies. , 2009, Journal of proteome research.

[52]  R. Elashoff,et al.  Surfactant Protein D and KL-6 as Serum Biomarkers of Interstitial Lung Disease in Patients with Scleroderma , 2009, The Journal of Rheumatology.

[53]  V. Aidinis,et al.  Gelsolin expression is necessary for the development of modelled pulmonary inflammation and fibrosis , 2009, Thorax.

[54]  R. Silver,et al.  Proteomic analysis of CTGF-activated lung fibroblasts: identification of IQGAP1 as a key player in lung fibroblast migration. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[55]  Paolo Spagnolo,et al.  A polymorphism in the CTGF promoter region associated with systemic sclerosis. , 2007, The New England journal of medicine.

[56]  T. Medsger,et al.  Changes in causes of death in systemic sclerosis, 1972–2002 , 2007, Annals of the rheumatic diseases.

[57]  F.-y. Liu,et al.  Effect of small interfering RNA on the expression of connective tissue growth factor and type I and III collagen in skin fibroblasts of patients with systemic sclerosis , 2006, The British journal of dermatology.

[58]  M. Morosini,et al.  Analysis of bronchoalveolar lavage fluid proteome from systemic sclerosis patients with or without functional, clinical and radiological signs of lung fibrosis , 2006, Arthritis research & therapy.

[59]  J. Malmström,et al.  Functional and phenotypical comparison of myofibroblasts derived from biopsies and bronchoalveolar lavage in mild asthma and scleroderma , 2006, Respiratory research.

[60]  N. Pedemonte,et al.  Gelsolin secretion in interleukin-4-treated bronchial epithelia and in asthmatic airways. , 2005, American journal of respiratory and critical care medicine.

[61]  D. Foell,et al.  Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells. , 2005, Blood.

[62]  E. Bargagli,et al.  Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis , 2005, Proteomics.

[63]  I. Thorey,et al.  MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. , 2004, Blood.

[64]  P. Janmey,et al.  The antimicrobial activity of the cathelicidin LL37 is inhibited by F-actin bundles and restored by gelsolin. , 2003, American journal of respiratory cell and molecular biology.

[65]  R. Strange,et al.  Glutathione S-transferase: genetics and role in toxicology. , 2000, Toxicology letters.

[66]  A. Prasse,et al.  Bronchoalveolar lavage proteomic analysis in pulmonary fibrosis associated with systemic sclerosis: S100A6 and 14-3-3&egr; as potential biomarkers , 2019, Rheumatology.

[67]  M. Ishizuka,et al.  Fragmented gelsolins are increased in rheumatoid arthritis-associated interstitial lung disease with usual interstitial pneumonia pattern. , 2016, Allergology international : official journal of the Japanese Society of Allergology.

[68]  I. Kheterpal,et al.  Gel-based and gel-free proteomic technologies. , 2011, Methods in molecular biology.

[69]  N. Inase,et al.  Proteome analysis of bronchoalveolar lavage fluid in lung fibrosis associated with systemic sclerosis. , 2010, Allergology international : official journal of the Japanese Society of Allergology.